NCT06488170 - A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Plaque Psoriasis

Interventions

DRUG

Tildrakizumab

As provided in real world clinical practice.

Trial Locations (7)

University Hospital Ostrava, Ostrava

Fakultní nemocnice Plzeň, with its registred seat at Edvarda Beneše, Pilsen

University Hospital Kralovske Vinohrady, Prague

University Hospital in Motol, Prague

General university hospital Prague, Prague

University Hospital Bulovka, Prague

Masarykova hospital Ústí nad Labem, Ústí nad Labem